The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.
 
Han Chong Toh
Employment - Tessa Therapeutics; Tessa Therapeutics
Leadership - Tessa Therapeutics
Stock and Other Ownership Interests - Tessa Therapeutics
Honoraria - Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Biosceptre International
Speakers' Bureau - Merck Sharp & Dohme
Research Funding - Tessa Therapeutics
Patents, Royalties, Other Intellectual Property - IP related to cancer immunotherapy for Tessa Therapeutics Ltd
Travel, Accommodations, Expenses - Tessa Therapeutics
 
Peter R. Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi; Sirtex Medical
Research Funding - Bayer (Inst); Bristol Myers Squibb Foundation (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Alan Nicholas
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Vincent Gaillard
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Roche/Genentech; Servier
Consulting or Advisory Role - Amgen; Celgene; HalioDx; Ipsen; Lilly; Merck Serono; Novartis; Pierre Fabre; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Merck Serono; Roche
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer